P7C3-A20

P7C3-A20, the fluorinated and methoxylated analog of the parent aminopropyl carbazole P7C3, is a synthetic neuroprotective compound identified through iterative structure-activity optimization of a chemical series originally discovered in a target-agnostic in vivo screen for enhancers of adult hippocampal neurogenesis conducted by Pieper, McKnight, and colleagues at the University of Texas Southwestern Medical Center [1]. The parent compound P7C3 was one of eight hits from a library of approximately 1,000 small molecules screened for their ability to augment the survival of newborn neurons in the subgranular zone of the murine dentate gyrus. Subsequent medicinal chemistry optimization, principally the replacement of the central hydroxyl with fluorine and the introduction of a methoxy substituent on the aniline ring, yielded P7C3-A20, which demonstrated approximately ten-fold greater proneurogenic potency than the parent compound while retaining favorable oral bioavailability, blood-brain barrier penetration, and tolerability in chronic dosing studies in rodents and nonhuman primates [2, 3]. The molecular target of P7C3-A20 was identified by Wang et al. (2014) as nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in the nicotinamide adenine dinucleotide (NAD+) salvage pathway [4]. P7C3-A20 functions as a positive allosteric modulator of NAMPT, enhancing the conversion of nicotinamide to nicotinamide mononucleotide (NMN) and thereby augmenting intracellular NAD+ levels under conditions of metabolic stress without elevating NAD+ to supraphysiologic concentrations. This mechanism distinguishes P7C3-A20 from direct NAD+ precursor supplementation strategies (nicotinamide riboside, nicotinamide mononucleotide) by preserving endogenous feedback regulation of the salvage pathway. The downstream consequences of NAMPT activation and NAD+ restoration include maintenance of sirtuin deacetylase activity (particularly SIRT1 and SIRT3), protection of mitochondrial bioenergetics, suppression of oxidative stress and DNA damage, attenuation of neuroinflammation through microglial modulation, and enhancement of the survival of newly generated neurons during adult hippocampal neurogenesis. The preclinical pharmacology of P7C3-A20 has been characterized across an unusually broad spectrum of neurodegenerative and neurotraumatic disease models. In the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson disease, P7C3-A20 substantially preserved dopaminergic neurons in the substantia nigra [5]. In the G93A-SOD1 transgenic mouse model of amyotrophic lateral sclerosis (ALS), P7C3-A20 reduced motor neuron cell death in the spinal cord [6]. In models of traumatic brain injury (TBI), P7C3-A20 blocked axonal degeneration and preserved neurological function when administered acutely [7], and, in a landmark 2020 study, restored blood-brain barrier integrity, arrested chronic neurodegeneration, and recovered normal cognitive function when treatment was initiated a full twelve months after the initial injury [8]. In rat models of focal ischemic stroke, P7C3-A20 promoted post-ischemic neurogenesis, restored cortical NAD+ levels, and improved chronic sensorimotor and cognitive outcomes [9]. In retinal degeneration models, the P7C3 class protected retinal ganglion cells from optic nerve injury [10]. In 2025, Vazquez-Rosa et al. published a study in Cell Reports Medicine demonstrating that P7C3-A20 treatment of 5xFAD and PS19 transgenic mice with advanced Alzheimer-like pathology produced comprehensive reversal of tau phosphorylation, blood-brain barrier deterioration, oxidative stress, DNA damage, and neuroinflammation, with full cognitive recovery and normalization of the clinical biomarker p-tau217 [11]. P7C3-A20 has not entered human clinical trials as of the most recent monograph revision. The compound is not approved by any regulatory authority for any indication. It is available as a research-grade preparation from multiple chemical suppliers at high purity. This monograph reviews the chemistry, synthesis, and structure-activity relationships of P7C3-A20; the NAMPT-mediated mechanism of action; the preclinical pharmacokinetic profile; the extensive preclinical pharmacology across neurodegenerative and neurotraumatic models; the current clinical development status; sourcing and quality considerations; reconstitution and handling; stack interactions; the adverse-event and safety profile from preclinical studies; and a comparative assessment of five neuroprotective or NAD-augmenting compounds against P7C3-A20 on five competency standards.